drugset / Trial / NCT03431168

A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV

NCT03431168

Phase 2 Completed 308 enrolled University of Alabama at Birmingham
RandomizedParallel-groupQuadruple-blindPrevention

Summary

More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.

Timeline

Start
2018-03-07
Primary completion
2021-01-01
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 1 g Oral
Comparator Bactrim Unknown Oral